血管生成素1和酪氨酸激酶受体2抑制剂对内皮细胞葡萄糖转运的作用及其机制

白冰 ,  张倩 ,  蒲涛 ,  倪宇 ,  胡婷婷 ,  胡琳弘 ,  杨亦彬

吉林大学学报(医学版) ›› 2025, Vol. 51 ›› Issue (06) : 1487 -1497.

PDF (1158KB)
吉林大学学报(医学版) ›› 2025, Vol. 51 ›› Issue (06) : 1487 -1497. DOI: 10.13481/j.1671-587X.20250605
基础研究

血管生成素1和酪氨酸激酶受体2抑制剂对内皮细胞葡萄糖转运的作用及其机制

作者信息 +

Effect of angiopoietin 1 and tyrosine kinase receptor 2 inhibitor on glucose transportation in endothelial cells and its mechanism

Author information +
文章历史 +
PDF (1185K)

摘要

目的 研究血管生成素1(Ang-1)和酪氨酸激酶受体2(Tie2)抑制剂对高糖培养人脐静脉内皮细胞(HUVECs)葡萄糖转运的作用,并阐明其作用机制。 方法 体外高糖(30 mmol·L-1)培养HUVECs,采用0、200、500、1 000和2 000 μg·L-1 Ang-1及0、2 500、5 000和7 500 nmol·L-1 Tie2抑制剂处理细胞,细胞计数试剂盒8(CCK-8)法检测细胞活性,筛选Ang-1和Tie2抑制剂最佳作用浓度。葡萄糖试剂盒检测Ang-1干预细胞后HUVECs上清液中葡萄糖水平。HUVECs细胞随机分为空白对照组(NG组)、高糖作用组(HG组)、HG+Tie2抑制剂组(HG+In-Tie2组)、HG+Ang-1组、HG+Ang-1+Tie2抑制剂组(HG+Ang-1+In-Tie2组)和HG+Ang-1+磷脂酰肌醇3-激酶(PI3K)抑制剂组(HG+Ang-1+LY294002组)。5-乙炔基-2'脱氧尿嘧啶核苷(EdU)法检测各组细胞增殖活性,恶唑黄/碘化丙啶(YO-PRO-1/PI)法检测各组细胞凋亡率,实时荧光定量PCR(RT-qPCR)法检测各组细胞中Ang-1Tie2 mRNA表达水平,Western blotting法检测各组细胞中Tie2、葡萄糖转运蛋白1(GLUT1)和葡萄糖转运蛋白4(GLUT4)蛋白表达水平及磷酸化PI3K(p-PI3K)/PI3K和磷酸化蛋白激酶(p-AKT)/AKT比值。 结果 CCK-8法检测,与0 μg·L-1 Ang-1比较,200 μg·L-1 Ang-1作用HUVECs 48 h后HUVECs细胞活性明显升高(P<0.01);与0 nmol·L-1 Tie2抑制剂比较,2 500、5 000和7 500 nmol·L-1 Tie2抑制剂作用下HUVECs细胞活性明显降低(P<0.01);Ang-1和Tie2抑制剂的最佳浓度分别为200 μg·L-1及2 500 nmol·L-1。与NG组比较,HG组HUVECs上清液中葡萄糖水平明显升高(P<0.01);与HG组比较,Ang-1组HUVECs上清液中葡萄糖水平明显降低(P<0.01)。EdU法检测,与NG组比较,HG组HUVECs增殖活性明显降低(P<0.01);与HG组比较,HG+In-Tie2组HUVECs增殖活性明显降低(P<0.01),HG+Ang-1组HUVECs增殖活性明显升高(P<0.01);与HG+Ang-1组比较,HG+Ang-1+In-Tie2组和HG+Ang-1+LY294002组HUVECs增殖活性均明显降低(P<0.01)。YO-PRO-1/PI法检测,与NG组比较,HG组HUVECs凋亡率明显升高(P<0.01);与HG组比较,HG+In-Tie2组HUVECs凋亡率明显升高(P<0.01),HG+Ang-1组HUVECs凋亡率明显降低(P<0.01);与HG+Ang-1组比较,HG+Ang-1+In-Tie2组和HG+Ang-1+LY294002组HUVECs凋亡率均明显升高(P<0.01)。RT-qPCR法检测,与NG组比较,HG组和HG+In-Tie2组HUVECs中Ang-1Tie2 mRNA表达水平均明显降低(P<0.01);与HG组比较,HG+In-Tie2组HUVECs中Ang-1Tie2 mRNA表达水平均明显降低(P<0.01),HG+Ang-1组HUVECs中Ang-1Tie2 mRNA表达水平均明显升高(P<0.05);与HG+Ang-1组比较, HG+Ang-1+In-Tie2组和HG+Ang-1+LY294002组HUVECs中Ang-1Tie2 mRNA表达水平均明显降低(P<0.05或P<0.01)。Western blotting法检测,与NG组比较,HG组HUVECs中Tie2蛋白表达水平明显降低(P<0.01),GLUT1和GLUT4蛋白表达水平均明显升高(P<0.01);与HG组比较,HG+In-Tie2组HUVECs中Tie2、GLUT1和GLUT4蛋白表达水平均明显降低(P<0.01),HG+Ang-1组HUVECs中Tie2蛋白表达水平明显升高(P<0.01),GLUT1和GLUT4蛋白表达水平均明显降低(P<0.01);与HG+Ang-1组比较,HG+Ang-1+In-Tie2组和HG+Ang-1+LY294002组HUVECs中Tie2、GLUT1和GLUT4蛋白表达水平均明显降低(P<0.01)。与NG组比较,HG组HUVECs中p-PI3K/PI3K和p-AKT/AKT比值均明显升高(P<0.01);与HG组比较,HG+In-Tie2组HUVECs中p-PI3K/PI3K和p-AKT/AKT比值均明显降低(P<0.01),HG+Ang-1组HUVECs中p-PI3K/PI3K和p-AKT/AKT比值均明显降低(P<0.01);与HG+Ang-1组比较,HG+Ang-1+In-Tie2组和HG+Ang-1+LY294002组HUVECs中p-PI3K/PI3K和p-AKT/AKT比值均明显降低(P<0.01)。 结论 Ang-1可下调高糖培养HUVECs中GLUT1和GLUT4的表达,Ang-1与Tie2结合可能过PI3K/AKT信号通路下调GLUT1和GLUT4参与高糖培养HUVECs的葡萄糖转运。

Abstract

Objective To study the effect of angiopoietin-1 (Ang-1) and tyrosine kinase receptor 2 (Tie2) inhibitor on glucose transportation in the human umbilical vein endothelial cells (HUVECs) cultured under high glucose conditions, and to clarify its mechanism. Methods The HUVECs were cultured in high glucose (30 mmol·L⁻¹) in vitro and treated with 0, 200, 500, 1 000, and 2 000 μg·L⁻¹ Ang-1 and 0, 2 500, 5 000, and 7 500 nmol·L⁻¹ Tie2 inhibitor; cell counting kit-8 (CCK-8) method was used to detect the cell activity to screen the optimal concentrations of Ang-1 and Tie2 inhibitor. Glucose kit was used to detect the glucose level in the supernatant of the HUVECs after Ang-1 intervention. The HUVECs were randomly divided into blank control group (NG group), high glucose group (HG group), HG+Tie2 inhibitor group (HG+In-Tie2 group), HG+Ang-1 group, HG+Ang-1+Tie2 inhibitor group (HG+Ang-1+In-Tie2 group), and HG+Ang-1+phosphatidylinositol 3-kinase(PI3K) inhibitor group (HG+Ang-1+LY294002 group). 5-Ethynyl-2'-deoxyuridine (EdU) method was used to detect the proliferation activities of the cells in various groups; YO-PRO-1/PI method was used to detect the apoptotic rates of the cells in various groups; real-time fluorescence quantitative PCR (RT-qPCR) method was used to detect the expression levels of Ang-1 mRNA and Tie2 mRNA in the cells in various groups; Western blotting method was used to detect the expression levels of Tie2, glucose transporter 1 (GLUT1), and glucose transporter 4 (GLUT4) proteins and the ratios of phosphorylated PI3K (p-PI3K)/PI3K and phosphorylated protein kinase B (p-AKT)/AKT in the cells in various groups. Results The CCK-8 assay results showed that compared with 0 μg·L⁻¹ Ang-1 group, the activity of the HUVECs was significantly increased after treated with 200 μg·L⁻¹ Ang-1 for 48 h (P<0.01); compared with 0 nmol·L⁻¹ Tie2 inhibitor group, the activity of the HUVECs was significantly decreased after treated with 2 500、 5 000 and 7 500 nmol·L⁻¹ Tie2 inhibitor (P<0.01); the optimal concentrations of Ang-1 and Tie2 inhibitor were 200 μg·L⁻¹ and 2 500 nmol·L⁻¹, respectively. Compared with NG group, the glucose level in the supernatant of the HUVECs in HG group was significantly increased (P<0.01); compared with HG group, the glucose level in the supernatant of the HUVECs in Ang-1 group was significantly decreased (P<0.01). The EdU assay results showed that compared with NG group, the proliferation activity of the HUVECs in HG group was significantly decreased (P<0.01); compared with HG group, the proliferation activity of the HUVECs in HG+In-Tie2 group was significantly decreased (P<0.01), and the proliferation activity of the HUVECs in HG+Ang-1 group was significantly increased (P<0.01); compared with HG+Ang-1 group, the proliferation activities of the HUVECs in HG+Ang-1+In-Tie2 group and HG+Ang-1+LY294002 group were significantly decreased (P<0.01). The YO-PRO-1/PI assay results showed that compared with NG group, the apoptotic rate of the HUVECs in HG group was significantly increased (P<0.01); compared with HG group, the apoptotic rate of the HUVECs in HG+In-Tie2 group was significantly increased (P<0.01), and the apoptotic rate of the HUVECs in HG+Ang-1 group was significantly decreased (P<0.01); compared with HG+Ang-1 group, the apoptotic rates of the HUVECs in HG+Ang-1+In-Tie2 group and HG+Ang-1+LY294002 group were significantly increased (P<0.01). The RT-qPCR results showed that compared with NG group, the expression levels of Ang-1 mRNA and Tie2 mRNA in the HUVECs in HG group and HG+In-Tie2 group were significantly decreased (P<0.01); compared with HG group, the expression levels of Ang-1 mRNA and Tie2 mRNA in HG+ In-Tie2 group were significantly decreased (P<0.01), and the expression levels of Ang-1 mRNA and Tie2 mRNA in the HUVECs in HG+Ang-1 group were significantly increased (P<0.05); compared with HG+Ang-1 group, the expression levels of Ang-1 mRNA and Tie2 mRNA in the HUVECs in HG+Ang-1+In-Tie2 group and HG+Ang-1+LY294002 group were significantly decreased (P<0.05 or P<0.01). The Western blotting results showed that compared with NG group, the expression level of Tie2 protein in the HUVECs in HG group was significantly decreased (P<0.01), and the expression levels of GLUT1 and GLUT4 proteins were significantly increased (P<0.01); compared with HG group, the expression levels of Tie2, GLUT1, and GLUT4 proteins in the HUVECs in HG+In-Tie2 group were significantly decreased (P<0.01), the expression level of Tie2 protein in the HUVECs in HG+Ang-1 group was significantly increased (P<0.01), and the expression levels of GLUT1 and GLUT4 proteins were significantly decreased (P<0.01); compared with HG+Ang-1 group, the expression levels of Tie2, GLUT1, and GLUT4 proteins in the HUVECs in HG+Ang-1+In-Tie2 group and HG+Ang-1+LY294002 group were significantly decreased (P<0.01). Compared with NG group, the p-PI3K/PI3K and p-AKT/AKT ratios in the HUVECs in HG group were significantly increased (P<0.01); compared with HG group, the p-PI3K/PI3K and p-AKT/AKT ratios in the HUVECs in HG+In-Tie2 group were significantly decreased (P<0.01), and the p-PI3K/PI3K and p-AKT/AKT ratios in the HUVECs in HG+Ang-1 group were significantly decreased (P<0.01); compared with HG+Ang-1 group, the p-PI3K/PI3K and p-AKT/AKT ratios in the HUVECs in HG+Ang-1+In-Tie2 group and HG+Ang-1+LY294002 group were significantly decreased (P<0.01). Conclusion Ang-1 down-regulates the expressions of GLUT1 and GLUT4 in the HUVECs cultured under high glucose conditions; the binding of Ang-1 to Tie2 may down-regulate GLUT1 and GLUT4 via the PI3K/AKT signaling pathway to participate in the glucose transportation in the HUVECs cultured under high glucose conditions.

Graphical abstract

关键词

糖尿病肾病 / 血管生成素1 / 葡萄糖转运蛋白 / 酪氨酸激酶受体2 / 磷脂酰肌醇3-激酶 / 蛋白激酶B

Key words

Diabetic nephropathy / Angiopoietin-1 / Glucose transporter protein / Tyrosine kinase receptor 2 / Phosphatidylinositol 3-kinase / Protein kinase B

引用本文

引用格式 ▾
白冰,张倩,蒲涛,倪宇,胡婷婷,胡琳弘,杨亦彬. 血管生成素1和酪氨酸激酶受体2抑制剂对内皮细胞葡萄糖转运的作用及其机制[J]. 吉林大学学报(医学版), 2025, 51(06): 1487-1497 DOI:10.13481/j.1671-587X.20250605

登录浏览全文

4963

注册一个新账户 忘记密码

糖尿病肾病(diabetic kidney disease,DKD)是糖尿病微血管病变所导致的肾脏结构和功能改变,确切发病机制虽尚不明确,但持续高血糖是糖尿病慢性血管并发症的中心环节,血管内皮层是高血糖首要的靶器官1。血管生成素1(angiopoietin 1,Ang-1)是血管生成素(angiopoietin,Ang)家族中主要成员之一。 酪氨酸激酶受体2(tyrosine kinase receptor 2,Tie2)是一种内皮细胞特异性受体,广泛表达于体内所有血管内皮细胞表面2。研究3-4表明:Ang-1与Tie2结合后通过激活磷脂酰肌醇3-激酶(phosphatidylinositol 3-kinase,PI3K)/蛋白激酶B(protein kinase B,AKT)信号通路,具有抑制内皮细胞凋亡、诱导内皮细胞迁移、促进血管成熟、维持血管稳定、降低血管通透性和抗炎等作用。胰岛素通过胰岛素受体底物(insulin receptor substrates, IRSs) 介导的胰岛素受体底物1(insulin receptor substrate-1,IRS-1)/PI3K/AKT信号通路在葡萄糖代谢中发挥作用5。葡萄糖的代谢取决于细胞对葡萄糖的摄取,但葡萄糖需借助胞膜上的葡萄糖转运蛋白(glucose transporter,GLUT)才可以自由地通过胞膜脂质双层结构。研究6发现:胰岛素通过PI3K激活AKT调控GLUT4的转运。CHANG等7在高糖培养的人主动脉内皮细胞中发现胰岛素通过IRS-1受体上调GLUT1的表达从而提高其葡萄糖摄取能力。本研究通过阻断Tie2,探讨Ang-1通过PI3K/AKT信号通路调节高糖培养人脐静脉内皮细胞(human umbilical vein endothelial cells,HUVECs)葡萄糖代谢的作用,旨在为DKD防治提供新思路和新靶点。

1 材料与方法

1.1 细胞、主要试剂和仪器

HUVECs(上海赛百慷生物技术股份有限公司)。胎牛血清(美国Gibco公司),甘露醇(上海阿拉丁生化科技股份有限公司),Ang-1、Tie2抑制剂和PI3K抑制剂LY294002(美国MedChemExpress公司),葡萄糖试剂盒(南京建成生物工程研究所),BeyoClickTM EdU-488试剂盒和YO-PRO-1/PI试剂盒(碧云天 生 物 公 司), 实 时 荧 光 定 量 PCR(real-time fluorescence quantitative PCR,RT-qPCR)试剂盒(武汉灵捷思生物技术有限公司),小鼠抗AKT抗体、 兔抗磷酸化AKT(phosphorylated AKT,p-AKT)(Ser473)抗体、兔抗Tie2抗体和小鼠抗β-Tubulin抗体(武汉Proteintech公司),兔抗磷酸化PI3K(phosphorylated PI3K,p-PI3K)p85 (Tyr458)[Tyr467]/p55(Tyr199)抗体、兔抗GLUT1抗体和兔抗GLUT4抗体(美国Affinity Biosciences公司),兔抗PI3K-p85抗体(美国Cell Signaling Technology公司),辣根过氧化物酶、山羊抗小鼠二抗和山羊抗兔二抗(武汉灵捷思生物技术有限公司)。CX41-32C02型倒置显微镜(日本Olympus 公 司), NanoDrop 1000(美 国 Thermo Scientic公司),CFX Connect RT-qPCR仪(美国Bio-Rad公司)。

1.2 细胞培养和Ang-1及Tie2抑制剂浓度筛选

将处于对数生长期的HUVECs按照每孔4×104个细胞的密度接种于6孔细胞培养板,按照文献[10-11]的方法培养24 h后,利用终浓度分别为0、200、500、1 000和2 000 μg·L-1 Ang-1分别培养24和48 h后,利用细胞计数试剂盒8(cell counting kit-8,CCK-8)法检测细胞活性,筛选Ang-1最佳作用浓度。将处于对数生长期的HUVECs按照每孔4×104个细胞的密度接种于6孔细胞培养板, 培养24 h后, 分别加入0、 2 500、5 000和7 500 nmol·L-1 Tie 2抑制剂预处理3 h,加入200 μg·L-1 Ang-1处理细胞48 h,利用CCK-8试剂盒检测细胞活性,筛选Tie2抑制剂最佳作用浓度。

1.3 实验分组

将处于对数生长期的HUVECs接种于6孔细胞培养板,随机分为空白对照组(NG组)、高糖作用组(HG组)、HG+Tie2抑制剂组(HG+In-Tie2组)、HG+Ang-1组、HG+Ang-1+Tie2抑制剂组(HG+Ang-1+In-Tie2组)和HG+Ang-1+PI3K抑制剂组(HG+Ang-1+LY294002组),其中NG组细胞利用含5.5 mmol·L-1葡萄糖的培养基(即低糖)培养48 h;HG组细胞利用30 mmol·L-1葡萄糖干预48 h;HG+In-Tie2组细胞在低糖培养条件下,2 500 nmol·L-1 Tie2抑制剂干预3 h 后,采用30 mmol·L-1葡萄糖干预48 h;HG+Ang-1组细胞在低糖培养条件下,200 μg·L-1 的Ang-1干预3 h 后,30 mmol·L-1葡萄糖干预细胞48 h;HG+Ang1+In-Tie2组细胞在低糖培养条件下,200 μg·L-1 Ang-1联合2 500 nmol·L-1 Tie2抑制剂干预3 h后,30 mmol·L-1葡萄糖干预48 h;HG+Ang-1+LY294002组细胞在低糖培养条件下,200 μg·L-1 Ang-1联合10 μmol·L-1 PI3K抑制剂LY294002作用3 h后,30 mmol·L-1葡萄糖干预48 h。LY294002浓度参考文献[8-12]。

1.4 CCK-8法检测细胞活性

HUVECs干预结束后,参考CCK-8试剂盒说明书加入CCK-8溶液,将细胞置于培养箱内继续培养1 h,采用酶标仪于波长450 nm处检测各组细胞的吸光度(A)值,计算各组细胞活性。细胞活性=(加药组A值-空白组A值)/(对照组A值-空白组A值)×100%。

1.5 试剂盒检测各组HUVECs上清液中葡萄糖水平

将处于对数生长期的HUVECs随机分为空白对照组(NG组)、高糖作用组(HG组)和Ang-1组;NG组细胞利用含5.5 mmol·L-1葡萄糖的培养基培养,HG组细胞利用含有30 mmol·L-1葡萄糖的培养基培养,Ang-1组利用200 μg·L-1 Ang-1处理细胞48 h。收集细胞,用分光光度计预热30 min,调节波长至 340 nm,参考试剂盒说明书进行加样,同时计时,在340 nm波长、37 ℃下孵育5 min的初始吸光度为A1,比色后将比色皿连同反应液一起放入37 ℃的水浴箱,5 min后记录340 nm波长下的吸光度为A2,计算ΔA,ΔA=A2-A1,葡萄糖水平(mmol·L-1)=(样品ΔA/校准品ΔA)×校准品浓度。

1.6 5-乙炔基-2'脱氧尿嘧啶核苷(5-ethynyl-2'-deoxyuridine,EdU)法检测各组细胞增殖活性

HUVECs干预后,参照EdU说明书加入EdU检测液,于培养箱中继续培养3~4 h后,吸去培养基,PBS缓冲液漂洗3次,每次5 min,4%多聚甲醛室温固定20 min,加入PI染色液,荧光显微镜观察,摄入EdU的细胞核呈绿色,即为阳性;未摄入EdU的细胞核呈蓝色。分别随机统计各组100个细胞中EdU阳性细胞的百分率,以EdU阳性细胞百分率代表各组细胞增殖活性。

1.7 恶唑黄/碘化丙啶(oxazole yellow/propidium lodide,YO-PRO-1/PI)检测各组细胞凋亡率

HUVECs干预后,加入YO-PRO-1/PI检测液,避光孵育5~20 min。孵育结束后,在荧光显微镜下观察荧光染色效果,YO-PRO-1染色阳性细胞为绿色荧光,激发波长(Ex)/发射波长(Em)=491/509 nm;PI染色阳性细胞为红色荧光,激发波长(Ex)/发射波长(Em)=535/617 nm,荧光显微镜下随机选取5个视野(左上、左下、右上、右下和中间,各40个细胞)共200个细胞,计算凋亡细胞所占百分率,即为细胞凋亡率。细胞凋亡率=(YO-PRO-1染色阳性细胞数+PI染色阳性细胞数)/200×100%。

1.8 RT-qPCR法检测各组HUVECs中Ang-1Tie2 mRNA表达水平

收集细胞,每组加入1 mL TRIzol试剂裂解细胞提取各组细胞总RNA,BeyoRT™ Ⅱ cDNA合成试剂盒合成cDNA后利用PCR试剂盒进行RT-qPCR法检测,反应步骤:94 ℃、5 min,94 ℃、15 s,56 ℃、25 s,72 ℃、10 s,35个循环;65 ℃、20 s,95 ℃、20 s。引物序列:Ang-1上游引物5'-CCACAACCTTGTC-AATCTTTGC-3',Ang-1下游引物5'-TTACAGT-CCAACCTCCCCCA-3';Tie2上游引物5'-CCCA-AGCCTTCCAAAACG-TG-3',Tie2下游引物5'- TTGCCCTCCCCAAT-CACATC-3';GAPDH上游引物5'-GCACAGTC-AAGGCCGAGAAT-3',GAPDH下游引物5'-GCCTTCTCCATGGTGGT-GAA-3'。以GAPDH为内参,采用2-ΔΔCt法计算目的基因表达水平。

1.9 Western blotting法检测各组细胞中p-AKT/AKT和p-PI3K/PI3K比值及GLUT1和GLUT4蛋白表达水平

HUVECs干预后,收集细胞,加入2 mL强度RIPA裂解后,4 ℃、10 000 r·min-1离心20 min,吸取细胞上清,蛋白定量后每孔按照20 μg总蛋白上样,SDS-PAGE电泳,NC转膜,小鼠抗AKT抗体(1∶800)、兔抗磷酸化AKT(Ser473)抗体(1∶500)、小鼠抗PI3K-p85抗体(1∶1 000)、兔抗Tie2抗体(1∶800)、小鼠抗Beta Tubulin抗体(1∶800)、兔抗GLUT1抗体(1∶1 200)、兔抗GLUT4抗体(1∶1 000)和兔抗p-PI3 Kinase p85抗体(1∶800),4 ℃孵育过夜,PBST缓冲液清洗3次,每次10~15 min,加入HRP酶标抗兔/抗鼠抗体孵育2 h。加入ECL发光液后进行扫描,采用Image J软件分析蛋白条带灰度值,以β-Tubulin为内参,计算目的蛋白表达水平。目的蛋白表达水平=目的蛋白条带灰度值/内参蛋白条带灰度值。

1.10 统计学分析

采用SPSS 21.0软件进行统计学分析。各组细胞增殖活性和凋亡率、细胞上清液中葡萄糖水平、各组细胞中Ang-1Tie2 mRNA表达水平及GLUT1和GLUT4蛋白表达水平以及p-AKT/AKT和p-PI3K/PI3K比值均符合正态分布且方差齐,以x±s表示多组间样本均数比较采用单因素方差分析,组间样本均数两两比较采用SNK- q检验。以P<0.05为差异有统计学意义。

2 结 果

2.1 Ang-1最佳浓度筛选

与0 μg·L-1 Ang-1比较,200 μg·L-1 Ang-1 作 用 HUVECs 48 h 后,HUVECs细胞活性明显升高(P<0.01), 其 他Ang-1浓度和作用时间HUVECs细胞活性差异无统计学意义(P>0.05)。同时参考文献[10],后续实验采用200 μg·L-1 Ang-1作为干预浓度。见表1

2.2 Tie2抑制剂最佳浓度筛选

与0 nmol·L-1 Tie2抑制剂比较,2 500、5 000和7 500 nmol·L-1 Tie2抑制剂作用下HUVECs细胞活性明显降低(P<0.01),同时参考文献[11],后续实验采用2 500 nmol·L-1 Tie2抑制剂作为干预浓度。见图1

2.3 各组HUVECs上清液中葡萄糖水平

与NG组比较,HG组HUVECs上清液中葡萄糖水平明显升高(P<0.01)。与HG组比较,Ang-1组HUVECs上清液中葡萄糖水平明显降低(P<0.01)。见图2

2.4 各组HUVECs的增殖活性

与NG组比较,HG组HUVECs增殖活性明显降低(P<0.01)。与HG组比较,HG+In-Tie2组HUVECs增殖活性明显降低(P<0.01),HG+Ang-1组HUVECs增殖活性明显升高(P<0.01)。与HG+Ang-1组比 较,HG+Ang-1+In-Tie2 组 和 HG+Ang-1+LY294002组HUVECs增殖活性均明显降低(P<0.01)。见图34

2.5 各组HUVECs凋亡率

与NG组比较,HG组HUVECs凋亡率明显升高(P<0.01)。与HG组比较,HG+In-Tie2组HUVECs凋亡率明显升高(P<0.01),HG+Ang-1组HUVECs凋亡率明显降低(P<0.01)。与HG+Ang-1组比较,HG+Ang-1+In-Tie2组和HG+Ang-1+LY294002组HUVECs凋亡率均明显升高(P<0.01)。见图56

2.6 各组HUVECs中Ang-1Tie2 mRNA表达水平

与NG组比较,HG组和HG+In-Tie2组HUVECs中Ang-1Tie2 mRNA表达水平均明显降低(P<0.01)。与HG组比较,HG+In-Tie2组HUVECs中Ang-1Tie2 mRNA表达水平均明显降低(P<0.01),HG+Ang-1组HUVECs中Ang-1Tie2 mRNA表达水平均明显升高(P<0.05)。与HG+Ang-1组比较,HG+Ang-1+In-Tie2组和HG+Ang-1+LY294002组HUVECs中Ang-1Tie2 mRNA表达水平均明显降低(P<0.05或P<0.01)。见表2

2.7 各组HUVECs中GLUT1、GLUT4和Tie2蛋白表达水平

与NG组比较,HG组HUVECs中Tie2蛋白表达水平明显降低(P<0.01),GLUT1和GLUT4蛋白表达水平均明显升高(P<0.01)。与HG组比较,HG+In-Tie2组HUVECs中Tie2、GLUT1和GLUT4蛋白表达水平均明显降低(P<0.01),HG+Ang-1组HUVECs中Tie2蛋白表达水平明显升高(P<0.01),GLUT1和GLUT4蛋白表达水平均明显降低(P<0.01)。与HG+Ang-1组比 较, HG+Ang-1+In-Tie2 组 和 HG+Ang1+LY294002组HUVECs中Tie2、GLUT1和GLUT4蛋白表达水平均明显降低(P<0.01)。见图7

2.8 各组HUVECs中p-PI3K/PI3K和p-AKT/AKT比值

与NG组比较,HG组HUVECs中p-PI3K/PI3K和p-AKT/AKT比值均明显升高(P<0.01)。与HG组比较,HG+In-Tie2组HUVECs中p-PI3K/PI3K和p-AKT/AKT比值均明显降低(P<0.01),HG+Ang-1组HUVECs中p-PI3K/PI3K和p-AKT/AKT比值均明显降低(P<0.01)。与HG+Ang-1组比较,HG+Ang-1+In-Tie2组和HG+Ang-1+ LY294002组HUVECs中p-PI3K/PI3K和p-AKT/AKT比值均明显降低(P<0.01)。见图8

3 讨 论

DKD是糖尿病最常见而严重的微血管并发症,其 发 病 率 呈 逐 年 增 长 趋 势,已 成 慢 性 肾 病(chronic kindey disease,CKD)最重要病因之一。已有学者证实血管内皮功能障碍与糖尿病慢性血管并发症有密切关联,蛋白尿的出现便是肾脏广泛微血管损害的标志13。血管内皮层是高血糖首要的靶器官,持续高血糖首先损伤血管内皮,导致入球和出球小动脉的阻力降低,引起肾小球滤过率增加和肾小球肥大,出现肾小球系膜区细胞外基质增生和小管间质纤维化,最终肾小球硬化并进入终末期肾病。Ang是一类调控血管形成的蛋白分子,至少有4个成员(Ang-1、Ang-2、Ang-3、Ang-4)。Ang-1常分布于血管、小肠、肾脏、前列腺、卵巢和子宫等多个组织。Tie2是Ang家族的共同受体,特异性表达于内皮细胞和酪激酶型造血干细胞,在胚胎时期的血管内皮中呈均匀表达14-15

Ang-1与Tie2结合具有抗内皮细胞凋亡,诱导迁移,降低通透性,从而促进血管新生和维持血管稳定的作用3。基于动物实验复杂性和诸多因素影响,以及血管内皮层是高血糖直接的靶器官,且国外大部分有关Tie2基因的体外实验研究也是建立在血管内皮细胞的基础上,因此本实验选用体外实验,以HUVECs为研究对象,因其具有多数内皮细胞的功能,并广泛应用于内皮细胞的相关研究。本研究结果显示:Tie2抑制剂作用HUVECs后,即表现出细胞增殖的抑制效应,当Tie2抑制剂作用浓度达2 500 nmol·L-1,其抑制增殖作用明显,并与已有研究11结果类似;而Ang-1能够促进HUVECs的增殖,浓度为200 μg·L-1时其促进细胞增殖的作用明显,并与已有研究10结果一致。同时葡萄糖水平检测实验结果显示:当Ang-1浓度 达 200 μg·L-1 时,其 降 糖 幅 度 明 显,故 选 取Tie2抑制剂及Ang-l的最佳药物干预浓度分别为2 500 nmol·L-1及200 μg·L-1。同时RT-qPCR和Western blotting 法 检 测 结 果 显 示: Tie2 在HUVECs中呈阳性表达,这为后续的研究奠定实验基础。

葡萄糖的代谢在于细胞对葡萄糖的摄取,但葡萄糖需借助胞膜上的GLUT才能得以实现。而目前发现至少存在5种GLUTs,其分布、亲合力及功能不尽相同。GLUT1主要分布在红细胞、血脑屏障及肿瘤组织中;GLUT2高表达在胰岛β细胞、小肠绒毛细胞基底膜侧、肾脏内皮细胞和肝脏细胞中;GLUT3主要表达在神经细胞,参与其能量代谢和调节;GLUT4属于胰岛素敏感性GLUTs,是脂肪细胞和骨骼肌细胞协助葡萄糖转运的主要蛋白质;GLUT5 主要表达于人类小肠刷状缘和肝脏,主要作为果糖转运体16。同样,在肾脏中发现了多种GLUT蛋白,其中GLUT1是表达最丰富的亚型之一,在DKD系膜细胞表型变化中起着关键的病理作用17。1型糖尿病大鼠肾组织中大鼠肾皮质GLUT1表达水平升高,导致细胞葡萄糖摄入增加、葡萄糖代谢增加、细胞肥大和细胞外基质(extracellular matrix,ECM)合成18。GLUT4是胰岛素作用后受调控最显著的GLUTs。在DKD早期足细胞中GLUT4表达上调,并与基线葡萄糖摄取增加和胰岛素反应性降低有关19。与野生型小鼠比较,GLUT4缺陷小鼠表现出更严重的蛋白尿和系膜细胞扩增20。本研究结果显示:正常葡萄糖浓度培养的HUVECs中GLUT1和GLUT4蛋白阳性表达,高糖培养后GLUT1和GLUT4蛋白表达明显上调,提示高糖可促使HUVECs中GLUT1和GLUT4蛋白表达上调。

Ang-1除具有抗内皮细胞凋亡及促进血管生成作用外,本课题组前期实验21发现其还可降低大鼠血糖,可见Ang-1与内皮细胞的糖代谢调控有关联,而且不受胰岛素的影响,提示Ang-1对DKD的保护作用可能还存在调控葡萄糖代谢因素的参与。Ang-1处理高糖培养HUVECs后,GLUT1和GLUT4蛋白表达水平较HG组降低,但仍明显高于NG组,因此Ang-1降低HUVECs上清液中葡萄糖水平可能与调整GLUT1和GLUT4蛋白表达有关联。

胰岛素是人体内降低血糖的重要激素,其调控血糖代谢极其复杂,涉及诸多信号传导通路,其中PI3K/AKT信号通路在胰岛素多种生物学功能中起重要调控作用22。Ang-1与Tie2结合,激活PI3K产生第二信使磷脂酰肌醇三磷酸(phosphatidylinositol 3-phosphate,PIP3),通 过 与AKT结合使其活化。活化的AKT通过磷酸化作用激活或抑制其下游一系列底物,如含半胱氨酸的天冬酸蛋白酶9(cystein aspartic acid specific protease-9,Caspase-9)、核因子κB(nuclear factor-κB,NF-κB)和糖原合成激酶 (glycogen synthase kinase,GSK)23等,从而发挥诱导内皮细胞迁移、抑制内皮细胞凋亡、维持血管稳定和降低血管通透性等作用23。Razuprotafib和AXT107就是通过上调Tie2活性,激活Tie2通路,从而抑制视网膜新血管形成,稳定视网膜和脉络膜血管24。由此推测Ang-1调控GLUT1和GLUT4蛋白表达可能与PI3K/AKT信号通路有关联,本研究通过阻断Tie2和PI3K以进一步观察PI3K、AKT、GLUT1和GLUT4的变化,结果显示:阻断Tie2后,细胞中GLUT1和GLUT4蛋白表达水平降低;阻断PI3K后GLUT1和GLUT4蛋白表达水平降低,提示Ang-1与Tie2结合影响GLUT1和GLUT4表达从而参与HUVECs上清液中的葡萄糖转运代谢。阻断Tie2后,HUVECs中p-PI3K/PI3K和p-AKT/AKT比值降低;阻断PI3K后,p-PI3K/PI3K和p-AKT/AKT比值降低,提示Ang-1与Tie2结合可通过PI3K/AKT通路参与HUVECs上清液中的葡萄糖转运代谢。

综上所述,Ang-1可影响高糖培养HUVECs中GLUT1和GLUT4蛋白表达,Ang-1与Tie2结合可能通过PI3K/AKT信号通路、借助GLUT1和GLUT4调节高糖培养HUVECs的葡萄糖代谢。后续研究还需通过动物实验探讨Ang-1如何影响GLUT1和GLUT4的表达进而降低血糖的机制并加以验证。

参考文献

[1]

WANG XSUN Z GFU Jet al. LRG1 loss effectively restrains glomerular TGF-β signaling to attenuate diabetic kidney disease[J]. Mol Ther202432(9): 3177-3193.

[2]

CASH ADE JAGER CBRICKLER Tet al. Endothelial deletion of EPH receptor A4 alters single-cell profile and Tie2/Akap12 signaling to preserve blood-brain barrier integrity[J]. Proc Natl Acad Sci U S A2023120(41): e2204700120.

[3]

LIN Y MMCCLENNAN AHOFFMAN L. Characterization of the ang/Tie2 signaling pathway in the diaphragm muscle of DMD mice[J]. Biomedicines202311(8): 2265.

[4]

ISAJI TOSUKA KOHMICHI Yet al. Expression of angiopoietins and angiogenic signaling pathway molecules in chronic subdural hematomas[J]. J Neurotrauma202037(23): 2493-2498.

[5]

JAYACHANDRAN MVINAYAGAM RXU B J. Guava leaves extract ameliorates STZ induced diabetes mellitus via activation of PI3K/AKT signaling in skeletal muscle of rats[J]. Mol Biol Rep202047(4): 2793-2799.

[6]

WU Z MYU W XNI W Jet al. Improvement of obesity by Liupao tea is through the IRS-1/PI3K/AKT/GLUT4 signaling pathway according to network pharmacology and experimental verification[J]. Phytomedicine2023110: 154633.

[7]

CHANG Y CCHAN M HYANG Y Fet al. Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression[J]. Cancer Lett2023563: 216179.

[8]

LIN F XYANG Y YWEI S Yet al. Hydrogen sulfide protects against high glucose-induced human umbilical vein endothelial cell injury through activating PI3K/Akt/eNOS pathway[J]. Drug Des Dev Ther202014: 621-633.

[9]

ZHANG W QZHA K KXIONG Yet al. Glucose-responsive, antioxidative HA-PBA-FA/EN106 hydrogel enhanced diabetic wound healing through modulation of FEM1b-FNIP1 axis and promoting angiogenesis[J]. Bioact Mater202330: 29-45.

[10]

ZHOU H YCHEN T TLI Y Jet al. Glycation of Tie-2 inhibits angiopoietin-1 signaling activation and angiopoietin-1-induced angiogenesis[J]. Int J Mol Sci202223(13): 7137.

[11]

HASENSTEIN J RKASMERCHAK KBUEHLER Det al. Efficacy of Tie2 receptor antagonism in angiosarcoma[J]. Neoplasia201214(2): 131-133.

[12]

HU Y QTAO R YCHEN Let al. Exosomes derived from pioglitazone-pretreated MSCs accelerate diabetic wound healing through enhancing angiogenesis[J]. J Nanobiotechnol202119(1): 150.

[13]

MURAKAMI YIKEDA YYONEMITSU Yet al. Inhibition of nuclear translocation of apoptosis-inducing factor is an essential mechanism of the neuroprotective activity of pigment epithelium-derived factor in a rat model of retinal degeneration[J]. Am J Pathol2008173(5): 1326-1338.

[14]

DU SQIAN J XTAN S Ret al. Tumor cell-derived exosomes deliver TIE2 protein to macrophages to promote angiogenesis in cervical cancer[J]. Cancer Lett2022529: 168-179.

[15]

MARIN VKAPLANSKI GGRÈS Set al. Endothelial cell culture: protocol to obtain and cultivate human umbilical endothelial cells[J]. J Immunol Meth2001254(1/2): 183-190.

[16]

SUADES AQURESHI AMCCOMAS S Eet al. Establishing mammalian GLUT kinetics and lipid composition influences in a reconstituted-liposome system[J]. Nat Commun202314: 4070.

[17]

ZHANG LWU M YZHANG J Zet al. The pivotal role of glucose transporter 1 in diabetic kidney disease[J]. Life Sci2024353: 122932.

[18]

DEEPA BVENKATRAMAN ANURADHA C. Effects of linalool on inflammation, matrix accumulation and podocyte loss in kidney of streptozotocin-induced diabetic rats[J]. Toxicol Mech Meth201323(4): 223-234.

[19]

YAGIN F HAL-HASHEM FAHMAD Iet al. Pilot-study to explore metabolic signature of type 2 diabetes: a pipeline of tree-based machine learning and bioinformatics techniques for biomarkers discovery[J]. Nutrients202416(10): 1537.

[20]

AN T FZHANG Z PXUE J Tet al. Interpretable machine learning identifies metabolites associated with glomerular filtration rate in type 2 diabetes patients[J]. Front Endocrinol202415: 1279034.

[21]

曹明燕. Angiopoietin-1 腺病毒载体构建及其在糖尿病大鼠肾脏的表达[D]. 遵义: 遵义医学院, 2009.

[22]

WANG LLIU W XHUANG X G. microRNA-199a-3p inhibits angiogenesis by targeting the VEGF/PI3K/AKT signalling pathway in an in vitro model of diabetic retinopathy[J]. Exp Mol Pathol2020116: 104488.

[23]

ALAWO D O ATAHIR T AFISCHER Met al. Regulation of angiopoietin signalling by soluble Tie2 ectodomain and engineered ligand trap[J]. Sci Rep20177: 3658.

[24]

NGUYEN Q DHEIER J SDO D Vet al. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye[J]. Int J Retina Vitreous20206(1): 48.

基金资助

国家自然科学基金项目(81860139)

贵州省卫健委科学技术基金项目(2024GZWJKJXM1070)

贵州省遵义市科技与大数据项目(遵市科合HZ字(2022)358号)

RIGHTS & PERMISSIONS

©《吉林大学学报(医学版)》编辑部,开放获取遵循CC BY-NC-ND协议。

AI Summary AI Mindmap
PDF (1158KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/